Korro Bio Inc. (KRRO)
21.58
-1.38 (-6.01%)
At close: Mar 04, 2025, 9:46 AM
No 1D chart data available
| Bid | 21.58 |
| Market Cap | 202.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.31M |
| EPS (ttm) | -9.44 |
| PE Ratio (ttm) | -2.29 |
| Forward PE | -3.71 |
| Analyst | Buy |
| Ask | 21.95 |
| Volume | 7,882 |
| Avg. Volume (20D) | 91,081 |
| Open | 22.64 |
| Previous Close | 22.96 |
| Day's Range | 20.71 - 22.95 |
| 52-Week Range | 20.71 - 98.00 |
| Beta | 2.13 |
About KRRO
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts....
Industry Biotechnology
Sector Healthcare
IPO Date Oct 3, 2019
Employees 95
Stock Exchange NASDAQ
Ticker Symbol KRRO
Website https://www.korrobio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for KRRO stock is "Buy." The 12-month stock price forecast is $125, which is an increase of 479.24% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
+3.34%
Korro Bio shares are trading higher. HC Wainwright...
Unlock content with
Pro Subscription
3 months ago
-15.55%
Korro Bio shares are trading lower. The company reported Q3 financial results.
